Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933765 | 1.00 | PDE4B (0.51) | PDE4BNR3C1PGRADORA1PDE4D | |
| SCHEMBL4931295 | 1.00 | PDE4B (0.51) | PDE4BNR3C1PGRADORA1PDE4D | |
| SCHEMBL4935550 | 0.94 | PDE4B (0.49) | PDE4BNR3C1PGRPDE4D | |
| SCHEMBL4935555 | 0.94 | PDE4B (0.49) | PDE4BNR3C1PGRPDE4D | |
| SCHEMBL4936389 | 0.93 | PDE4B (0.52) | PDE4BNR3C1PGRADORA1PDE4D | |
| SCHEMBL4927710 | 0.91 | PDE4B (0.59) | PDE4BPDE4D | |
| SCHEMBL4935841 | 0.90 | PDE4B (0.52) | PDE4BNR3C1PGRADORA1PDE4D | |
| SCHEMBL4935970 | 0.90 | PDE4B (0.52) | PDE4BNR3C1PGRADORA1PDE4D | |
| SCHEMBL14533688 | 0.89 | PDE4B (0.51) | PDE4BNR3C1PGRADORA1PDE4D | |
| SCHEMBL4934526 | 0.89 | PDE4B (0.51) | PDE4BNR3C1PGRADORA1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | claimed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885NR3C1 90/4885PGR 619/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | PDE4B 1/4885NR3C1 827/4885PGR 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.